HLA-E coding and 3′ untranslated region variability determined by next-generation sequencing in two West-African population samples

2015 ◽  
Vol 76 (12) ◽  
pp. 945-953 ◽  
Author(s):  
Erick C. Castelli ◽  
Celso T. Mendes-Junior ◽  
Audrey Sabbagh ◽  
Iane O.P. Porto ◽  
André Garcia ◽  
...  
PLoS ONE ◽  
2016 ◽  
Vol 11 (2) ◽  
pp. e0150311 ◽  
Author(s):  
Kamila Caraballo Cortes ◽  
Osvaldo Zagordi ◽  
Joanna Jabłońska ◽  
Agnieszka Pawełczyk ◽  
Natalia Kubisa ◽  
...  

PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e9684
Author(s):  
Nkechi Martina Odogwu ◽  
Oladapo O. Olayemi ◽  
Akinyinka O. Omigbodun

Accurate characterization of the vaginal microbiome remains a fundamental goal of the Human Microbiome project (HMP). For over a decade, this goal has been made possible deploying high-throughput next generation sequencing technologies (NGS), which indeed has revolutionized medical research and enabled large-scale genomic studies. The 16S rRNA marker-gene survey is the most commonly explored approach for vaginal microbial community studies. With this approach, prior studies have elucidated substantial variations in the vaginal microbiome of women from different ethnicities. This review provides a comprehensive account of studies that have deployed this approach to describe the vaginal microbiota of African women in health and disease. On the basis of published data, the few studies reported from the African population are mainly in non-pregnant post pubertal women and calls for more detailed studies in pregnant and postnatal cohorts. We provide insight on the use of more sophisticated cutting-edge technologies in characterizing the vaginal microbiome. These technologies offer high-resolution detection of vaginal microbiome variations and community functional capabilities, which can shed light into several discrepancies observed in the vaginal microbiota of African women in an African population versus women of African descent in the diaspora.


2020 ◽  
Vol 11 (05) ◽  
pp. 232-238
Author(s):  
Marcus Kleber

ZUSAMMENFASSUNGDas kolorektale Karzinom (KRK) ist einer der häufigsten malignen Tumoren in Deutschland. Einer frühzeitigen Diagnostik kommt große Bedeutung zu. Goldstandard ist hier die Koloskopie. Die aktuelle S3-Leitlinie Kolorektales Karzinom empfiehlt zum KRK-Screening den fäkalen okkulten Bluttest. Für das Monitoring von Patienten vor und nach Tumorresektion werden die Messung des Carcinoembryonalen Antigens (CEA) und der Mikrosatellitenstabilität empfohlen. Für die Auswahl der korrekten Chemotherapie scheint derzeit eine Überprüfung des Mutationsstatus, mindestens des KRAS-Gens und des BRAF-Gens, sinnvoll zu sein. Eine Reihe an neuartigen Tumormarkern befindet sich momentan in der Entwicklung, hat jedoch noch nicht die Reife für eine mögliche Anwendung in der Routinediagnostik erreicht. Den schnellsten Weg in die breite Anwendung können Next-Generation-Sequencing-basierte genetische Tests finden.


Sign in / Sign up

Export Citation Format

Share Document